의료용 콜드체인 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the healthcare cold chain market size is projected to expand from USD 124.53 billion in 2025 and USD 137.27 billion in 2026 to USD 223.39 billion by 2031, registering a CAGR of 10.23% between 2026 to 2031.

This report is Segmented by Product Type (Vaccines, Biopharmaceuticals, Clinical Trial Materials, Blood & Plasma Products, and Cell & Gene Therapies), Service Type (Transportation, Storage & Warehousing, and More), End User (Pharmaceutical & Biopharma Companies, Hospitals & Healthcare Providers and More), and Geography (North America, Europe, and More). The Market and Forecasted in Terms of Value (USD).

Global Healthcare Cold Chain Market Trends and Insights

Rising Demand for Biologics and Specialty Drugs Accelerates Cold Chain Infrastructure

Biologics now anchor investment priorities in the healthcare cold chain market as 43% of drugs approved over 2018 2023 required refrigerated or frozen handling, which raises operating rigor from fill finish to last mile. Temperature excursions can degrade protein-based therapies, so validated storage, lane qualification, and continuous temperature monitoring are central to protecting product integrity and patient safety. Compliance frameworks such as USP 1079 reinforce risk-based controls for storage and transportation and call for robust performance qualification that reflects worst-case conditions. WHO vaccine packaging and shipping guidance, together with PQS equipment specifications, also inform equipment choices, acceptance testing, and lane procedures for international shipments in the healthcare cold chain market. Packaging investment is scaling in response, with industry vendors reporting strong multi-year growth in insulated shippers, phase change materials, and vacuum insulated panels aligned to tougher qualification standards. The healthcare cold chain market benefits from this shift since biologics pipelines sustain recurring replenishment cycles, wider geographic distribution, and tighter compliance baselines across manufacturers and 3PLs.

Global Vaccine Expansion Drives Distributed Cold Chain Networks

Expanded immunization programs are reshaping the healthcare cold chain market as Gavi-supported countries protected 72 million children in 2024 and recorded USD 255 million in co-financing, which signals durable national ownership of vaccine budgets. HPV coverage in lower-income countries rose from 3% in 2019 to 25% in 2024, with 32.6 million girls immunized in 2024, more than double the prior year, which increases demand for refrigerated transport and storage at subnational levels.Gavi also reported progress on measles and DTP3 coverage in 2024, though pockets of zero-dose children remain, which underscores the need for resilient last-mile equipment and power solutions in fragile and conflict-affected settings. WHO's Essential Program on Immunization recommends medical-grade refrigerators with forced air circulation, backup power, and temperature mapping to identify hot and cold spots, all of which improve inventory integrity in primary health centers. WHO PQS prequalified solar direct drive vaccine refrigerators and freezers offer reliable performance in off-grid locations and align with energy resilience priorities in distributed networks. As programs widen coverage and introduce more antigens, the healthcare cold chain market gains from scaled replenishment, upgraded equipment fleets, and broader transport lanes, especially for national immunization programs and partners.

High Operational and Infrastructure Costs Constrain Capacity Expansion

Operating costs weigh on near-term margin structure as refrigeration power is the dominant warehouse load, and energy expenses make up a large share of cold storage operating costs for the healthcare cold chain market. Vendors also report steady rent inflation and capacity tightness since 2019, which lifts carrying costs and complicates network design in legacy real estate. Labor remains a structural pressure where GxP-trained roles are scarce, and wage rates rise, which increases dependence on automation and digital monitoring in storage and in transit. Temperature excursions impose major economic risk as industry sources estimate significant annual losses from cold chain failures, which reinforces the case for better packaging, visibility, and standard work in the healthcare cold chain market. Dry ice and liquid nitrogen procurement can also be volatile at the corridor level, so shippers diversify sources and optimize charging protocols to stabilize supply. Packaging specifications continue to evolve with the use of high-performance insulation and phase change materials to hold lane performance under more stringent qualification regimes, a trend reinforced by supplier guidance and customer validation programs.

Other drivers and restraints analyzed in the detailed report include:

1. IoT, Real Time Visibility, and Predictive Analytics Transform Passive Monitoring into Active Intervention
2. Cell and Gene Therapy Scale Up Requires ULT and Cryogenic Networks
3. Regulatory Complexity and Fragmented Compliance Standards Elevate Administrative Burden

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Vaccines accounted for 37.23% of the healthcare cold chain market share in 2025 as routine immunization and pandemic preparedness drove steady replenishment and last-mile traffic. Gavi-supported countries protected 72 million children in 2024 and achieved record co-financing, which boosted volumes across countries and subnational warehouses. HPV coverage climbed to 25% in 2024 across lower-income countries, with 32.6 million girls vaccinated that year, which widened recurring demand for 2°C to 8°C capacity in district stores and clinics. WHO's Essential Program on Immunization frames equipment and operating standards and guides the upgrade path from domestic fridges to medical-grade units with forced air circulation and backup power. Temperature requirements differ by antigen class as most vaccines ship at 2°C to 8°C while some viral vaccines ship frozen, and mRNA products may need ultra cold lanes, so lane design must align with product label and qualification evidence in the healthcare cold chain market. WHO PQS prequalified solar direct drive refrigerators and freezers improve service continuity in off-grid areas and reduce dependence on bottled gas or unstable mains power.

Cell and gene therapies post the steepest growth trajectory through 2031, supported by approvals, late stage trials, and specialized logistics that require cryogenic handling. The healthcare cold chain market size for cell and gene therapies is projected to expand at a 10.80% CAGR through 2031 as programs scale and more centers come online. Cryogenic shipping under -150°C relies on liquid nitrogen dry shippers with multilayer qualification, GPS tracking, and chain of identity controls to eliminate mix ups in batch of one workflows. Commercial shipments carry high value per movement, so playbooks emphasize redundancy on dewars, lanes, and carriers as part of risk mitigation in the healthcare cold chain market. Cryoport's sale of CRYOPDP to DHL in June 2025 broadened the specialty courier footprint while allowing Cryoport to focus on integrated regenerative medicine services and storage, and it strengthened network options for CGT customers. With more late phase trials in flight, commercial launches will add to demand for validated cryogenic networks that integrate with manufacturing sites, treatment centers, and regional depots.

Geography Analysis

North America holds 38.60% of the 2025 healthcare cold chain market, supported by U.S. leadership in biologics manufacturing, strong FDA-aligned compliance practices, and broad adoption of IoT visibility. The region benefits from large-scale investments across distribution centers, dedicated healthcare fleets, and specialized cryogenic services that match the complexity of CGT and biologics portfolios in the healthcare cold chain market. Cencora's USD 1 billion program includes a 530,000 square foot national distribution center in Ohio that is scheduled for spring 2027 and a large increase in refrigerated capacity in Alabama scheduled for fall 2026, which lifts throughput and resilience. UPS Healthcare's acquisitions of Frigo Trans and BPL expand temperature-controlled capabilities within Pan European corridors and reinforce integrated coverage for North American shippers with Europe-bound flows, ranging from cryogenic to controlled room temperatures. With continued emphasis on real-time visibility and route optimization, operators aim to compress exception rates and stabilize on-time performance in the healthcare cold chain market.

Europe is a major hub for compliant distribution due to rigorous GDP expectations and strong biologics consumption across Germany, Switzerland, and the United Kingdom. DHL's EUR 2 billion (USD 1.16 billion) program to expand its airfreight cold chain network includes a dedicated 777 freighter between Brussels and Cincinnati and pharma only zones at BRUcargo, which enhances bidirectional connectivity with the United States in the healthcare cold chain market. UPS expanded its European cold chain capability via Frigo Trans and BPL, which adds certified lanes and warehousing that span -196°C to +25°C and tightens control across handoffs. Cencora is improving its Pan European logistics footprint through partnerships and new facilities planned for 2026, which increases options for specialty distribution and trial supply in the healthcare cold chain market. Industry investment patterns and regulatory alignment continue to raise service standards while keeping focus on audit readiness, validated equipment, and orchestrated exception handling.

Asia Pacific is projected to post the fastest regional growth rate at a 13.89% CAGR through 2031 as manufacturers scale in China and India and as regional hubs in Singapore, Japan, and South Korea add specialized capacity. The healthcare cold chain market size in Asia Pacific is therefore set to expand as more facilities come online with GMP compliant storage and cryogenic services for advanced therapies and clinical research. DHL allocated EUR 500 million for Asia Pacific through 2030 and opened a EUR 10 million dedicated pharmaceutical hub in Singapore in February 2026 with specialized temperature zones from cryogenic to ambient near Tuas Biomedical Park. The Singapore facility includes GMP compliant infrastructure that supports biologics, vaccines, and clinical trial logistics, which strengthens a regional anchor for the healthcare cold chain market. Governments in Southeast Asia are investing in capacity and digitalization, including new cold stores in the Philippines and route optimization with solar powered equipment and telemetry in Indonesia, which reduce spoilage risk and raise visibility. WHO guidance continues to shape equipment selection and qualification, helping health systems raise last mile reliability in the healthcare cold chain market.

1. Berlinger & Co. AG
2. Biocair International Ltd.
3. Cencora, Inc.
4. CEVA Logistics AG
5. Controlant ehf.
6. Cryoport, Inc.
7. DHL Group (Deutsche Post AG)
8. DSV A/S
9. ELPRO?BUCHS AG
10. FedEx Corporation
11. Kerry Logistics Network Limited
12. Kuehne+Nagel International AG
13. Nippon Express Holdings, Inc.
14. Sensitech (Carrier)
15. SF Express Co., Ltd.
16. UPS Healthcare (United Parcel Service, Inc.)
17. Yusen Logistics Co., Ltd.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Demand for Biologics and Specialty Drugs
  • 4.2.2 Global Vaccine Expansion and Immunization Programs
  • 4.2.3 Growth of Clinical Trials and Decentralized/Direct-To-Patient Logistics
  • 4.2.4 Technological Advancements in IoT, Real-Time Visibility, and Analytics
  • 4.2.5 Sustainability Mandates Reshaping Procurement and Packaging
  • 4.2.6 Cell & Gene Therapy Scale-Up Requiring ULT/Cryogenic Networks
• 4.3 Market Restraints
  • 4.3.1 High Operational and Infrastructure Costs
  • 4.3.2 Regulatory Complexity and Compliance Burden
  • 4.3.3 Dry ice/LN2 Supply Volatility and Cost Shocks
  • 4.3.4 Certified Lane/Airport Capacity Bottlenecks for Pharma Air Cargo
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porters Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Bargaining Power of Suppliers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Product Type
  • 5.1.1 Vaccines
  • 5.1.2 Biopharmaceuticals
  • 5.1.3 Clinical Trial Materials
  • 5.1.4 Blood & Plasma Products
  • 5.1.5 Cell & Gene Therapies
• 5.2 By Service Type
  • 5.2.1 Transportation
  • 5.2.2 Storage & Warehousing
  • 5.2.3 Packaging solutions
  • 5.2.4 Monitoring & tracking systems
• 5.3 By End User
  • 5.3.1 Pharmaceutical & Biopharma Companies
  • 5.3.2 Hospitals & Healthcare Providers
  • 5.3.3 Research & Academic Institutes
  • 5.3.4 CROs / Clinical Trial Organizations
• 5.4 By Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 India
    • 5.4.3.3 Japan
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Berlinger & Co. AG
  • 6.3.2 Biocair International Ltd.
  • 6.3.3 Cencora, Inc.
  • 6.3.4 CEVA Logistics AG
  • 6.3.5 Controlant ehf.
  • 6.3.6 Cryoport, Inc.
  • 6.3.7 DHL Group (Deutsche Post AG)
  • 6.3.8 DSV A/S
  • 6.3.9 ELPRO?BUCHS AG
  • 6.3.10 FedEx Corporation
  • 6.3.11 Kerry Logistics Network Limited
  • 6.3.12 Kuehne+Nagel International AG
  • 6.3.13 Nippon Express Holdings, Inc.
  • 6.3.14 Sensitech (Carrier)
  • 6.3.15 SF Express Co., Ltd.
  • 6.3.16 UPS Healthcare (United Parcel Service, Inc.)
  • 6.3.17 Yusen Logistics Co., Ltd.

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment